Researchers have identified that α-synuclein plays a role in DNA repair in neurons and that disruption of this function could lead to widespread death of neurons.
Browsing: Movement disorders
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
Take a look behind the scenes of a recent paper in Biomarkers in Medicine as we ask the author about oligomeric α-synuclein in basal tears of Parkinson’s patients.
A new mouse model of Parkinson’s has demonstrated how the disease could spread from the gut to the brain through the vagus nerve.
Researchers have identified the earliest signs of Parkinson’s disease in the brain, many years before patients show any symptoms.
In this interview, Anders Björklund speaks to us about how we might overcome the current limitations of using stem cell therapies for Parkinson’s disease.
Researchers from the University of Oregon (OR, USA) suggest that noninvasive EEG readings could present as easily detectable biomarkers to help diagnose and improve treatment for Parkinson’s and other motor disorders.
In this interview, we spoke with Viviane Labrie about her research into the vermiform appendix as a possible contributor to Parkinson’s disease.
Whilst at the AD/PD™ conference, we had the pleasure of speaking with Patrik Brundin about his talk on novel therapeutic targets for Parkinson’s disease.
People who were previously housebound with Parkinson’s disease are now able to walk more freely thanks to spinal stimulation treatment.